Results 131 to 140 of about 13,748 (197)

Impact of Long-Term Structured Exercise on Body Composition in an NTRK Fusion-Positive NSCLC Patient Treated With Entrectinib. [PDF]

Thorac Cancer
Avancini A, Sposito M, Adamoli G, Borsati A, Ciurnelli C, Scaglione IM, Eccher S, Toniolo L, Tregnago D, Longo L, Insolda J, Milella M, Schena F, Pilotto S, Belluomini L.   +14 more
europepmc   +1 more source

Fusion-Negative NTRK Overexpression Exhibit Biological Relevance in Colorectal Cancer: Implications for Prediction of Responses to Kinase Inhibitors. [PDF]

Pharmaceuticals (Basel)
Alfahed A.
europepmc   +1 more source

Low-grade NTRK-rearranged spindle cell neoplasm presenting as a colonic polyp and managed by polypectomy: a rare case report and literature review. [PDF]

Diagn Pathol
Evaristo G, Setia N, Wang P, Pytel P, Alpert L.   +4 more
europepmc   +1 more source

Extraskeletal osteosarcoma harboring ETV6::NTRK3 fusion treated successfully with larotrectinib: a case study. [PDF]

Commun Med (Lond)
Skok K, Ochsenhofer F, Gassner R, Leithner A, Szkandera J, Viertler C, Hasenschwandtner S, Reichinger A, Liegl-Atzwanger B.   +8 more
europepmc   +1 more source

Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments-A Comprehensive Review. [PDF]

Cancer Med
Chen A, Li S, Guo C, Gu C, Gui J, Deng Y, Feng X, Mi Y.   +7 more
europepmc   +1 more source

Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion. [PDF]

Oncologist
Akrout F, Bogumil H, Yedeas MD, Sievers P, Touat M, Achoura S.   +5 more
europepmc   +1 more source

Septic shock and hepatic hemorrhage in <i>NTRK</i>-fusion retroperitoneal sarcoma: a case report on oncologic emergencies. [PDF]

AME Case Rep
Wan YL, Wang T, Liu D, Li J, Yang J, Su H, Zhang QZ, Huang L.   +7 more
europepmc   +1 more source

Case Report: Novel findings of larotrectinib in children with <i>NTRK</i>-rearranged spindle cell tumor. [PDF]

Front Oncol
Wu L, Xie W, Wang J, Lu S, Zhang Y, Huang J.   +5 more
europepmc   +1 more source

Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing. [PDF]

ESMO Open
Vanacker H, Brahmi M, Pissaloux D, Meurgey A, Karanian M, Feng X, Le Loarer F, Ray-Coquard I, Waissi W, Paindavoine S, Houlier A, Corradini N, Blay JY, Tirode F, Dufresne A.   +14 more
europepmc   +1 more source

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions. [PDF]

Oncol Res
Rubinstein M, Hong ML, Nanda RK, Jones DT, Aboaid H, Myat YM, Thein KZ.   +6 more
europepmc   +1 more source